Arkolith/Insider Trading/CBAY/Form 4

Shah Sujal

Chief Executive Officer, DirectorCymaBay Therapeutics, Inc. (CBAY) · full profile →Form 4 · filed Mar 22, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
15
2 non-derivative · 13 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 22, 2024Disposed to issuer(D)310K——0
Mar 22, 2024Disposed to issuer(D)96K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 22, 2024Disposed to issuer(D)358K——0
Mar 22, 2024Disposed to issuer(D)800K——0
Mar 22, 2024Disposed to issuer(D)650K——0
Mar 22, 2024Disposed to issuer(D)285K——0
Mar 22, 2024Disposed to issuer(D)536K——0
Mar 22, 2024Disposed to issuer(D)314K——0
Mar 22, 2024Disposed to issuer(D)147K——0
Mar 22, 2024Disposed to issuer(D)621K——0
Mar 22, 2024Disposed to issuer(D)90K——0
Mar 22, 2024Disposed to issuer(D)48K——0
Mar 22, 2024Disposed to issuer(D)50K——0
Mar 22, 2024Disposed to issuer(D)39K——0
Mar 22, 2024Disposed to issuer(D)88K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-035447) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML